CK1ε Is Required for Breast Cancers Dependent on β-Catenin Activity

• So Young Kim ,

  Contributed equally to this work with: So Young Kim, Ian F. Dunn

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Broad Institute, Cambridge, Massachusetts, United States of America

  ⨯
• Ian F. Dunn ,

  Contributed equally to this work with: So Young Kim, Ian F. Dunn

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, Broad Institute, Cambridge, Massachusetts, United States of America

  ⨯
• Ron Firestein,

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Broad Institute, Cambridge, Massachusetts, United States of America

  ⨯
• Piyush Gupta,

  Affiliation Broad Institute, Cambridge, Massachusetts, United States of America

  ⨯
• Leslie Wardwell,

  Affiliation Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America

  ⨯
• Kara Repich,

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Broad Institute, Cambridge, Massachusetts, United States of America

  ⨯
• Anna C. Schinzel,

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Broad Institute, Cambridge, Massachusetts, United States of America

  ⨯
• Ben Wittner,

  Affiliations Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States of America, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Serena J. Silver,

  Affiliation Broad Institute, Cambridge, Massachusetts, United States of America

  ⨯
• David E. Root,

  Affiliation Broad Institute, Cambridge, Massachusetts, United States of America

  ⨯
• Jesse S. Boehm,

  Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Broad Institute, Cambridge, Massachusetts, United States of America

  ⨯
• Sridhar Ramaswamy,

  Affiliations Broad Institute, Cambridge, Massachusetts, United States of America, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States of America, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America, Harvard Stem Cell Institute, Cambridge, Massachusetts, United States of America

  ⨯
• Eric S. Lander,

  Affiliation Broad Institute, Cambridge, Massachusetts, United States of America

  ⨯
• William C. Hahn

  * E-mail: William_Hahn@dfci.harvard.edu

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Broad Institute, Cambridge, Massachusetts, United States of America

  ⨯